A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
Stopped early · Phase 1 · Has a placebo group
Conditions studied: Steatohepatitis
In brief
The purpose of this study is to measure the safety, tolerability, and PK (measurement of drug activity in the body over time) of AZD7503 injected subcutaneously, and compared to placebo, in participants with suspected NASH, a type of liver disease.
Key facts
- Study ID
- NCT05864391
- Run by
- AstraZeneca
- People needed
- 40
- Starts
- 2023-03-31
- Expected to finish
- 2024-03-20
- Last updated by the study team
- 2025-07-20
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Chandler, Arizona, United States
- Research Site — Montclair, California, United States
- Research Site — Hialeah, Florida, United States
- Research Site — Port Orange, Florida, United States
- Research Site — Atlanta, Georgia, United States
- Research Site — Morehead City, North Carolina, United States
- Research Site — Houston, Texas, United States
- Research Site — San Antonio, Texas, United States
- Research Site — San Antonio, Texas, United States
- Research Site — San Juan, Puerto Rico
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.